Srinivasu Poondru

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

Alfredo Berruti, Éric Baudin, Michael J. Demeure et al. · The Lancet Oncology · 2015 · 332 citations · Full text

Oncology, Pharmacology, Clinical Trials +6

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

Ronan J. Kelly, Anish Thomas, Arun Rajan et al. · Annals of Oncology · 2013 · 171 citations · Full text

Phase I/ii Study, Medicine, Pharmacology +8

A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors

Igor Puzanov, Colin R. Lindsay, Laura W. Goff et al. · Clinical Cancer Research · 2014 · 95 citations

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Robin L. Jones, Edward S. Kim, Pilar Nava-Parada et al. · Clinical Cancer Research · 2014 · 93 citations

Lecithin vesicles for topical delivery of diclofenac

Ramesh Boinpally, Sen‐Lin Zhou, Srinivasu Poondru et al. · European Journal of Pharmaceutics and Biopharmaceutics · 2003 · 88 citations

Medicine, Lecithin Vesicles, Topical Drug +3